Cargando…

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

BACKGROUND: Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of ‘platinum-sensitive’ ovarian cancer and has been shown to improve progre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ledermann, J.A., Embleton-Thirsk, A.C., Perren, T.J., Jayson, G.C., Rustin, G.J.S., Kaye, S.B., Hirte, H., Oza, A., Vaughan, M., Friedlander, M., González-Martín, A., Deane, E., Popoola, B., Farrelly, L., Swart, A.M., Kaplan, R.S., Parmar, M.K.B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903311/ https://www.ncbi.nlm.nih.gov/pubmed/33610123 http://dx.doi.org/10.1016/j.esmoop.2020.100043

Ejemplares similares

Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application
por: Embleton-Thirsk, Andrew, et al.
Publicado: (2019)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
por: Raja, F A, et al.
Publicado: (2011)

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
por: Stark, Dan P., et al.
Publicado: (2017)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
por: Oza, Amit M, et al.
Publicado: (2015)

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
por: González Martín, Antonio, et al.
Publicado: (2019)

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
por: Sahebjam, S, et al.
Publicado: (2013)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

Impact of retrospective data verification on the results of the academic-led ICON6 trial
por: Embleton, Andrew, et al.
Publicado: (2015)

Retinoids in Oncology
por: Rustin, G.J.S.
Publicado: (1994)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer
por: Hawarden, Amy, et al.
Publicado: (2023)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
por: Suffredini, Dante A., et al.
Publicado: (2018)

In-Flight Performance of the ICON EUV Spectrograph
por: Korpela, Eric J., et al.
Publicado: (2023)

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib
por: Pommier, A J C, et al.
Publicado: (2014)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Phonological iconicity
por: Schmidtke, David S., et al.
Publicado: (2014)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma
por: Lobo, Merryl R., et al.
Publicado: (2015)

Biogeosciences Perspectives on Integrated, Coordinated, Open, Networked (ICON) Science
por: Dwivedi, D., et al.
Publicado: (2022)

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
por: Stark, Dan, et al.
Publicado: (2013)

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
por: Clamp, Andrew R, et al.
Publicado: (2022)

Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
por: Lobo, Merryl R., et al.
Publicado: (2014)

GeoHealth Perspectives on Integrated, Coordinated, Open, Networked (ICON) Science
por: Barnard, M. A., et al.
Publicado: (2022)

International Consensus (ICON): allergic reactions to vaccines
por: Dreskin, Stephen C., et al.
Publicado: (2016)

ICON: Eosinophil Disorders
por: Valent, Peter, et al.
Publicado: (2012)

In Flight Performance of the Far Ultraviolet Instrument (FUV) on ICON
por: Frey, H. U., et al.
Publicado: (2023)

Limits to the usability of iconic memory
por: Rensink, Ronald A.
Publicado: (2014)

Neutral Composition Information in ICON EUV Dayglow Observations
por: Tuminello, Richard M., et al.
Publicado: (2022)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture
por: Jiang, Yanyan, et al.
Publicado: (2015)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
por: Lheureux, Stephanie, et al.
Publicado: (2023)

Sample size calculation for randomized selection trials with a time‐to‐event endpoint and a margin of practical equivalence
por: Dehbi, Hakim‐Moulay, et al.
Publicado: (2022)

Icones Roumaines
por: Nicolescu, Corina
Publicado: (1971)

ICON: chronic rhinosinusitis
por: Bachert, Claus, et al.
Publicado: (2014)

Sensitivity study for ICON tidal analysis
por: Cullens, Chihoko Y., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kfkie769su4eb1fc1cnkghtdco